CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
regorafenibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02080260
NCT02080260Phase 2Completed
CompareCT.gov

A Pilot Study Testing Single-Agent Regorafenib in Advanced Previously-Treated Adenocarcinoma of the Pancreas

Wake Forest University Health Sciences·interventional·Posted Mar 6, 2014·Updated Apr 21, 2022

In Brief

A Phase 2 clinical trial evaluating regorafenib for Pancreatic Cancer. Completed, enrolled 20 participants across 12 sites.

Detailed Summary

This study tests regorafenib as a single agent in the treatment of metastatic pancreatic cancer patients who have progressed after prior chemotherapy with gemcitabine. The prognosis for these patients is particularly grim, no other standard treatment options exist, and novel approaches are desperately needed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Cancer
CountriesUnited States
CollaboratorsBayer

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 6, 2014
Enrollment StartJun 6, 2014
Primary CompletionJun 28, 2017
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 12.3 years ago

Interventions

regorafenibdrug

Single agent drug therapy with regorafenib